Sign in
CompletedNo phase

The Effect of the CytoSorb® Filter to Remove Anticoagulants From the Circulation During Emergency Surgery for Aortic Dissection

Key facts

Who runs it
Oslo University Hospital
Where
Norway1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
11 people enrolled
Started
18 Apr 2021
Ended
5 Nov 2024
Type of study
Observational
Record updated
14 May 2025

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Indication for urgent surgery for proximal aortic disease
  • Treatment with FXa inhibitor for more than 2 weeks
  • Measured concentration of FXa inhibitor in therapeutic range (>50 ng/mL) at the time of admission
  • Intraoperative use of Cytosorb® hemadsorber

Who cannot take part

  • Low FXa inhibitor concentration (<50 ng/mL) at the time of admission

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The direct oral anticoagulants (DOACs) and particularly the FXa inhibitors are a concern in patients presenting with type A aortic dissection as this may contribute to severe bleeding complications. The antidote andexanet alfa (Ondexxya®) can interact with the heparin- anti-thrombin III (ATIII) complex which may neutralize the anticoagulant effect of heparin and the use of andexanet alfa before surgery necessitating heparin-anticoagulation has been reported to cause unresponsiveness to heparin. The investigators have preliminary in-vitro data demonstrating the ability to remove apixaban from reconstituted blod by hemadsorption and are now analyzing if aFXa inhibitor levels may be reduced by hemadsorption in the clinical setting analyzing this in patients using FXa inhibitors being operated acutely for type A aortic dissection.

The group in the trial

  • Study group

    Due to catastrophic bleeding events in patients who are anticoagulated with FXa inhibitors undergoing emergency surgery on the proximal aorta and lack of antidote (not available in Norway and most likely not compatible with heparin), the department has decided to use hemadsorber in these cases.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
14 May 2025